Immune checkpoint inhibitors, particularly anti-PD1/PD-L1 therapies, have transformed the management of advanced melanomas, including mucosal subtypes, by demonstrating superior survival outcomes compared to traditional therapies [58,71]. The gene discussed is CD274; the disease is melanoma.